FMP
PTC Therapeutics, Inc.
PTCT
NASDAQ
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
54.5 USD
1.74 (3.19%)
2024 Q4
2024 Q3
2024 Q2
2024 Q1
213.17M
196.79M
186.7M
210.12M
16.28M
10.85M
18.39M
66.27M
196.89M
185.94M
168.31M
143.85M
359.28M
240.45M
201.67M
189.4M
124.77M
161.41M
132.17M
116.13M
84.68M
73.46M
69.5M
73.27M
0
0
0
0
0
0
0
0
149.82M
5.58M
-2.02M
1.59M
-162.39M
-54.51M
-33.36M
-45.55M
67.69M
-43.48M
-45.52M
-39.14M
-94.7M
-97.99M
-85.73M
-84.7M
-28.81M
8.66M
13.45M
6.88M
-65.89M
-106.65M
-99.18M
-91.58M
-0.86
-1.39
-1.29
-1.2
-0.86
-1.39
-1.29
-1.2
76.85M
76.93M
76.73M
76.5M
76.85M
76.93M
76.73M
76.5M
-46.88M
-54.51M
-35.23M
11.53M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
-3.58B
-3.47B
-3.38B
-3.28B
-65.89M
-106.65M
-99.18M
-91.58M
0
0
0
0
0
0
0
0
-3.65B
-3.58B
-3.47B
-3.38B
-65.89M
-106.65M
-99.18M
-91.58M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
117.66M
122.64M
123.12M
183.97M
6.76M
6.49M
7.02M
55.4M
-6.5M
54.24M
7.38M
-64.35M
117.39M
61.91M
108.73M
192.92M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
0
0
0
0
82.34M
82.34M
82.34M
82.34M
82.34M
82.34M
82.34M
82.34M
All figures are in USD.